Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
0.74-0.02 (-2.61%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.76
Bid0.73 x 7900
Ask0.74 x 300
Day's Range0.70 - 0.79
52wk Range0.70 - 4.32
1y Target EstN/A
Market Cap42.2M
P/E Ratio (ttm)-1.32
Avg Vol (3m)639,371
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Ampio Updates Clinical and Regulatory Activity

    ENGLEWOOD, Colo., Sept. 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the Company has met with the CBER Division of the FDA to seek guidance on the best path forward to obtain a Biological License for Ampion™ to treat patients suffering from pain caused by severe osteoarthritis of the knee (OAK). Michael Macaluso, Ampio's CEO noted, "We are grateful to CBER for their thorough review of our data, which referenced over 1800 patients across multiple trials. CBER's guidance included a number of very good options and as a result, we are continuing discussions.

  • PR Newswire23 days ago

    Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion™ in New Clinical Indications

    Dr. David Bar-Or, Ampio's Chief Scientific Officer, explained: "We reported an important positive effect of Ampion™ on stabilization of alpha tubulin (a cytoskeleton protein involved in trafficking molecules inside the cell and important in controlling vascular permeability) in retinal endothelial cells and described the mechanism of action of Ampion™ and a resulting decrease in leakage of fluid through these cells which normally line the interior of blood vessels in the retina.

  • PR Newswirelast month

    Ampio Reports Additional Peer-Reviewed Publication on Ampion™

    ENGLEWOOD, Colo., Aug. 30, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion™ in the treatment of Osteoarthritis. Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports that in the presence of either IL-1β or TNFα, LMWF-5A (Ampion™) increased the expression of both COX2 mRNA and protein, and this increase was significant compared to that observed with IL-1β- or TNFα-stimulated, saline-treated cells.